Kornimate/medical-research-clean huggingface dataset:
thromboelastometry and ischemic stroke (thrombopredict)

Conditions: Cerebrovascular Stroke; Thrombolytic Therapy; Mechanical Thrombectomy

Summary: in ischemic stroke, the recanalization rate after intravenous thrombolysis has been estimated to be less than 50% in patients with proximal intracranial artery occlusion; this rate is greater than 80% after endovascular thrombectomy. thromboelastometry is a method of analysis of coagulation and fibrinolysis in whole blood. the main objective of this study is to evaluate whether the parameters obtained by thromboelastometry are predictive of revascularization at arteriography during mechanical thrombectomy, after treatment with rt-pa thrombolysis.

this is a single-center prospective observational study at the university hospital of caen. any patient presenting a neurological deficit of sudden onset, compatible with a ischemic stroke diagnosed on brain imaging and eligible for thrombolysis by rtpa and/or a endovascular thrombectomy procedure will be included. clot formation kinetics will be assessed by thromboelastometry (rotem® and/or quantra®) to determine the predictive parameters of revascularization. the parameters of clot formation and lysis as well as revascularization according to thrombo-inflammation processes will be studied.

Eligibility criteria:
inclusion criteria: * age \> 18 years * diagnosis of ischemic stroke * decision of intravenous thrombolysis and/or endovascular thrombectomy by the neurologist and/or interventional neuroradiologist. * patient admitted to the emergency department during the hours and days when the hematology-biology laboratory is open (monday to friday from 8:30 a.m. to 6:30 p.m.) * no opposition to the research from the patient or his relatives * inclusions according to the emergency procedure exclusion criteria: * age \< 18 ans * formal contraindication to thrombolysis and/or endovascular thrombectomy, disorders of hemostasis and anticoagulant treatment.

Keywords: thromboelastometry ischemic stroke biomarker thrombolysis endovascular thrombectomy prediction of revascularization
effect of orthokeratology versus spectacles on myopia progression in chinese children: a crossover trial

Conditions: Myopia

Summary: orthokeratology is becoming popular for the treatment of myopia children. many studies have shown that orthokeratology is effective in temporarily reducing refractive error, and is also helpful for controlling myopia progression. however, the mechanism for its slowing myopia progression and rebound effect after the treatment have not been clearly studied. in addition, the effect of orthokeratology among chinese children has not been evaluated with randomized controlled trial.this study is to assess the effect of orthokeratology versus spectacles on myopia progression in school-aged chinese children during two years.


Eligibility criteria:
inclusion criteria: * ages eligible for study: 7 years to 14 years * genders eligible for study: both * visual acuity 20/20 or better in each eye * spherical error ranging from -0.5 d to -5.0 d and astigmatism less than 1.5 d in each eye, anisometropia less than 1.0 d between the two eyes * no strabismus, amblyopia and any other ocular or systematic diseases that may affect refractive development exclusion criteria: * currently or history using other interventions to control myopia progression (acupuncture, drugs, contact lens, ear needles and so on) * unable to cooperate with the ocular examination,questionnaire survey,or orthokeratology wearing

Keywords: myopia progression orthokeratology
randomized controlled trial comparing standard versus positive pressure nebulization in infants with bronchiolitis to reduce hospital admissions

Conditions: Bronchiolitis

Summary: hypothesis: that administration of nebulized therapy for bronchiolitis when using positive airway pressure is superior to standard mask ventilation in reducing hospital admissions. bronchiolitis is a lower respiratory tract infection (lrti) syndrome caused by a variety of different viruses. it is the most common lrti in children under 24 months old. multiple studies have documented variation in treatment, hospitalization rates, and length of hospital stay for bronchiolitis, suggesting a lack of consensus and an opportunity to improve care for this common disorder. research to determine optimal delivery methods of respiratory medications that may augment oxygenation by decreasing atelectasis (lung cell collapse) and increasing oxygen saturation have not been done. currently bronchodilators are delivered through a passive process, inhaled as they are nebulized (made from liquid into gas) into a face mask. this study will evaluate whether using a newly developed positive pressure nebulization device that uses pressure to expand lung cells and, hypothetically, deliver the medication better, improves oxygenation by reducing atelectasis (lung cell collapse) to decrease hospitalization in infants with moderate to severe bronchiolitis. positive pressure nebulization is a relatively new adaptation of a previously existing modality, and is already currently in use here at pch.


Eligibility criteria:
inclusion criteria: * infants 2-24 months with moderate to severe bronchiolitis exclusion criteria: * those outside the age range of 2-24 months, or less than postconceptual age of 48weeks for premature infants * those with comorbid conditions such as cyanotic heart disease, home oxygen use, tracheostomy use, or other serious medical conditions. * those with history of apnea
a study of herceptin (trastuzumab) in patients with metastatic or advanced gastric cancer with disease progression

Conditions: Gastric Cancer

Summary: this study will evaluate the efficacy and safety of herceptin in patients with metastatic or advanced gastric cancer with disease progression during platinum-based or 5-fluoropyrimidine-based chemotherapy. the anticipated time on study treatment is until disease progression.


Eligibility criteria:
inclusion criteria: * adult patients 18-75 years of age; * metastatic or advanced gastric cancer; * disease progression under or after 1 prior platinum-based or 5-fluoropyrimidine-based chemotherapy for metastatic disease; * \>=4 weeks from last platinum-based or fluoropyrimidine-based chemotherapy; * \>=1 measurable lesion; * her2 overexpression (ihc \[2+\] or \[3+\]). exclusion criteria: * concurrent chemotherapy or immunotherapy; * brain or meningeal metastases; * clinically significant cardiac disease, advanced pulmonary disease or severe dyspnoea; * co-existing malignancies or malignancies diagnosed within last 5 years, except basal cell cancer or cervical cancer in situ; * women who are pregnant or breastfeeding.
imaging of facial neuritis

Conditions: Facial Neuritis

Summary: improved means of positive diagnosis of facial neuritis, the leading cause of peripheral facial palsy


Eligibility criteria:
inclusion criteria: * age 18-80 years * subject giving their consent for their participation * patients with neuritis facial (neuritis group) who benefited, between 2009 and 2016, from an mri of the internal auditory ducts, with gadolinous product injection and on the mri 3 tesla * patients with a perception deafness, without neuritis sign (control group) who also benefited from an mri with gadolinous product injection on the mri 3t with the same protocol. exclusion criteria: - refusal to participate in the study

Keywords: facial neuritis t2 weighted gradient-echo fast imaging employing steady state acquisition (fiesta-c) magnetic resonance imaging (mri)
neuro-ophthalmology and autoimmune encephalitis (node)

Conditions: Autoimmune Encephalitis

Summary: autoimmune encephalitis represents a group of rare and heterogeneous neurological disorders. pathophysiological mechanisms in these diseases are still unknown. recently, oculomotor and neurovisual disorders have been described. cerebral areas and neuronal networks associated with these abnormalities are well described. the investigator proposes to study and describe such neuro-ophthalmological disorders in a prospective cohort of patients with a autoimmune encephalitis, to better understand the pathophysiological basis of this neurological condition.


Eligibility criteria:
inclusion criteria: * diagnosis of autoimmune encephalitis * with or without pathological antibody * aged from 18 to 70 years old * able to understand the aims and methods of this project * non opposed to the participation of this study exclusion criteria: * other neurological, psychiatric or systemic conditions, which could induce neuro-ophthalmological signs cognitive impairment, which is not linked to autoimmune encephalitis * ophthalmological condition, which could modify the interpretation of neuro-ophthalmological data inability to remain seated * pregnancy or breast feeding * adults under guardianship
intensive physiotherapy in children affected by posterior fossa tumors

Conditions: Posterior Fossa Tumor

Summary: the objective of the current study is to describe the effectiveness of conventional and intensive physiotherapeutic intervention in improving gross motor skills (i.e. postural changes, walking and balance skills) in children affected by posterior fossa tumors

the surgery aimed to remove tumors located in the cranial posterior fossa can lead, as a consequence, to a clinical condition of ataxia. children affected by this condition are commonly referred to physiotherapy treatment, even though the level of scientific evidence in the field of motor rehabilitation is still lacking. the objective of the current study is to describe the effectiveness of conventional and intensive physiotherapeutic intervention in improving gross motor skills (i.e. postural changes, walking and balance skills) in children affected by posterior fossa tumors. by conventional physiotherapy intervention we mean a therapeutic path with a 1:1 operator-patient ratio and which does not make use of robotic or virtual reality devices. by intensive we mean that it occurs twice a day, 5 days a week, for a duration of four weeks. given the high variability in the severity of the clinical pictures, the primary objective will be the patient's improvement in gross motor skills as a whole, which will be identified with the gross motor function measurment (gmfm) scale. changes will also be monitored with respect to the autonomy and assistive care in the daily life of the recruited patients (scored through weefim or fim), the risk of fall (scored through the pediatric balance scale) and with a sign-specific scale on ataxia (scale for assessment and rating of ataxia) finally, for walking patients, walking resistance will be assessed through the 6 minute walking test (6mwt)

Eligibility criteria:
inclusion criteria: * subjects who underwent to surgical resection of tumors located in posterior fossa, age between 0 and 25 years exclusion criteria: * subjects that are currently addressed to rehabilitative protocols availing of technological devices
promotion of exercise and health in obesity

Conditions: Obesity

Summary: the primary objectives of this randomized clinical trial are a) to implement and test the impact of a 1-year lifestyle obesity treatment program based on self-determination theory on 3-year change in physical activity and motivation for exercise/physical activity, body weight and fat, and selected eating variables, b) to identify behavioral and psychosocial theory-based moderators or mediators of primary outcomes, especially physical activity and body weight.

obesity and sedentary lifestyles are worldwide threats to public health but feasible and effective strategies to tackle these problems are scarce. the identification of variables that explain why only a sub-group of overweight persons succeeds at increasing physical activity and achieving long-term weight control is a key research topic in exercise and sports sciences. subjects are 260 healthy women (bmi, 25 to 40 kg/m2), aged between 25 and 50 years, premenopausal, of whom half receive the treatment intervention, the remaining being randomly assigned to a control group at baseline. this rct consists of a 1-year intervention plus a 2-year no contact follow-up period. the intervention group attended 30 weekly group sessions, designed to follow sdt basic tenets, covering pa, eating/nutrition, body image, and other cognitive and behavioral contents. central to the intervention model are autonomy, intrinsic motivation, and self-regulation of behavior change. autonomy-supportive treatment climate and internal causality orientations are predicted to enhance autonomous regulation, perceived competence, and intrinsic motivation for the targeted behaviors, resulting in lasting behavioral and body weight changes. the intervention was designed to follow sdt, with an emphasis on promoting intrinsic, self-regulated motivation for exercise and weight control. the control group received a general health education curriculum based on several 3- to 6-week long educational topics (e.g. food safety, stress management, self-care, body image, and others). results are expected to contribute to a better understanding of how individual characteristics, particularly those related to physical activity and exercise influence success, better screening/readiness testing procedures, improved matching of interventions to participants, and lower rates of attrition and unsuccessful weight loss attempts.

Eligibility criteria:
inclusion criteria: * female (25-50 years old) * pre-menopausal * bmi between 25 and 40 kg/m2 * willing to attend weekly meetings (during 1 year) * willing to not participate in other formal or informal weight loss program during the first year of the study (intervention group only). exclusion criteria: * major/chronic illness * taking (or having taken in the previous year) medication known to interfere with body weight regulation, including anti-depressive medication

Keywords: behavioral, self-determination theory, motivational interviewing, exercise, physical activity, motivation, moderators, mediators, predictors, weight
atrial fibrillation general registry

Conditions: Atrial Fibrillation

Summary: given the advances in atrial fibrillation (af) management and the availability of new european society of cardiology (esc) guidelines, there is a need for the systematic collection of contemporary data regarding the management and treatment of af in the member esc countries. it is now nearly 10 years since the last european registry of af management was undertaken (as part of the esc euro heart survey programme), and a new registry was needed.

given the advances in atrial fibrillation (af) management and the availability of new european society of cardiology (esc) guidelines, there is a need for the systematic collection of contemporary data regarding the management and treatment of af in the member esc countries. it is now nearly 10 years since the last european registry of af management was undertaken (as part of the esc euro heart survey programme), and a new registry was needed. new guidelines on the management of af have recently been published by the esc, but it remains unclear how often clinicians adhere to them. since the last euro heart survey, a change in management strategy has necessitated an update on prevalent management practices in af. this is influenced by clinical availability of catheter ablation as a routine procedure and new antiarrhythmic drugs, and also by developments in stroke thromboprophylaxis and medical therapy options. under the eurobservational research programme (eorp), an af ablation sentinel pilot registry was launched in 2010. a survey of af management under the eorp programme will enable a timely assessment of the uptake of the new esc guidelines, allow monitoring of implementation and uptake of catheter ablation, new antithrombotic drugs and new antiarrhythmic agents, and will inform about outcomes related to guideline-adherent management of af.

Eligibility criteria:
inclusion criteria: * patients will be officially enrolled in the study only if ecg diagnosis of af has been made. * the qualifying episode of af should have occurred within one year before the date of baseline. * af is the primary or secondary diagnosis, i.e. the current admission / visit may be due to other reasons. * patients need not be in af at the time of enrolment. * signed patient inform consent if applicable. exclusion criteria: * no ecg/holter with af recorded. * only atrial flutter recorded. * the qualifying episode of af occurred more than one year before the date of baseline. * age \<18 years. * patients are already included in the esc atrial fibrillation long-term registry if your centre was enrolled in the pilot phase. * patients who are currently or are planned to be taking part in a cardiac clinical trial.
effect of eplerenone on endothelial function in patients with stable coronary heart disease

Conditions: Coronary Artery Disease

Summary: the aim of the present study is to investigate wether endothelial dysfunction associated with stable coronary artery disease is altered by selective aldosterone antagonism with eplerenone as potential anti-inflammatory drug versus placebo. additionally we hypothesize that selective aldosterone antagonism reduces systemic inflammatory response such as c-reactive proteine, oxidative stress and pro-inflammatory cytokines.


Eligibility criteria:
inclusion criteria: * male patients (\> 30 years of age) with history of coronary artery disease (documented by coronary angiogram, nuclear imaging, positive stress test) * stable cardiovascular medication for at least 4 months evaluation of the patients will take place at the department of internal medicine, cardiology, university hospital zurich. exclusion criteria: * evidence for myocardial infarction, unstable angina, stroke within 3 months prior to study entry * coronary intervention/re-vascularisation procedure within 3 months prior to study entry * long acting nitrates * uncontrolled arterial hypertension, defined as rr\>160/90 mmhg * congestive heart failure (\> nyha i) * ejection fraction \<50% * av-block\>i˚ * creatinine clearance \<50 ml/min * insulin-dependent diabetes mellitus * type 2 diabetes with microalbuminuria * age \< 30 years * anemia (hb\<10 g/dl) * malignancy chronic infection * smoking * serum potassium \>5.5 meq/l * drug abuse * potassium supplements or potassium-sparing diuretics (amiloride, spironolactone, or triamterene) * concomitant use of strong inhibitors of cyp450 3a4 (e.g., ketoconazole, itraconazole) * known history of cushing disease or morbus addisons or diseases of the thyroid gland

Keywords: eplerenone auf die endothelfunktion bei patienten mit stabiler koronarer herzkrankheit
prospective trial of induction immunotherapy in locally advanced or oligometastatic nsclc without a primary curative option

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: in a certified lung- cancer center, patients with nsclc and a potentially curative stage (including patients with oligometastatic disease) are prospectively enrolled if curative treatment (either definitive radio-chemotherapy or resection) cannot be performed due to large tumor size or for functional reasons. for these patients, the multidisciplinary tumor board (mdb) recommends immuno-(chemo)therapy and re-evaluation. response is assessed radiologically including pet-ct if indicated. after review of the mdb, patients receive either definitive curative treatment or palliative treatment.

in a certified lung- cancer center, patients with nsclc and a potentially curative stage (including patients with oligometastatic disease) are prospectively enrolled if curative treatment (either definitive radio-chemotherapy or resection) cannot be performed due to large tumor size or for functional reasons (e. g. too large radiation field or functionally inoperable for the required resection). for these patients, the multidisciplinary tumor board (mdb) recommends immuno-(chemo)therapy and re-evaluation. response is assessed radiologically including pet-ct if indicated. after review of the mdb, patients receive either definitive curative treatment or palliative treatment.

Eligibility criteria:
inclusion criteria: * newly diagnosed nsclc * histologically or cytologically proven * stage iii - iva (oligometastatic) by complete staging * ecog 0-2 * life expectancy 3 months * ability to provide written informed consent exclusion criteria: * primary resectability * primary definitive chemoradiotherapy feasible

Keywords: immunotherapy, chemoradiotherapy, resection, pd-l1
study of aro-apoc3 (plozasiran) in adults with familial chylomicronemia syndrome (fcs)

Conditions: Familial Chylomicronemia

Summary: the purpose of aroapoc3-3001 is to evaluate the efficacy and safety of aro-apoc3 plozasiran) in adult participants with familial chylomicronemia syndrome (fcs). participants who have met all eligibility criteria will be randomized to receive 4 doses of plozasiran or matching placebo administered subcutaneously. participants who complete the randomized period will continue in a 2-year open-label extension period where all participants will receive plozasiran.


Eligibility criteria:
inclusion criteria: * fasting tg ≥ 10 mmol/l (≥ 880 mg/dl) at screening refractory to standard lipid lowering therapy * diagnosis of fcs * willing to follow dietary counseling as per investigator judgement based on local standard of care * participants of childbearing potential (males \& females) must use highly-effective contraception during the study and for at least 24 weeks following the last dose of study medication. males must not donate sperm during the study and for at least 24 weeks following the last dose of study medication * women of childbearing potential must have a negative pregnancy test at screening and cannot be breastfeeding * women of childbearing potential on hormonal contraceptives must be stable on the medication for ≥ 2 menstrual cycles prior to day 1 exclusion criteria: * current use or use within the last 365 days from day 1 of any hepatocyte-targeted sirna or antisense oligonucleotide molecule * diabetes mellitus newly diagnosed within 12 weeks of screening or where hba1c ≥ 9.0% at screening * active pancreatitis within 12 weeks before day 1 * history of acute coronary syndrome event within 24 weeks of day 1 * history of major surgery within 12 weeks of day 1 * uncontrolled hypertension * on treatment with human immunodeficiency virus (hiv) antiretroviral therapy * seropositive for hepatitis b virus (hbv) or hepatitis c virus (hcv) * new york heart association (nyha) clas ii, iii, or iv heart failure note: additional inclusion/exclusion criteria may apply per protocol